Bristol Myers Squibb launches Sotyktu at an 86% discount, reducing the price to $950 for cash-paying U.S. patients.
Browsing: Market Access
Updates on pricing, reimbursement, HTA decisions, and access policies affecting global healthcare markets.
Trump drug price deadline prompts pharma firms to announce initiatives, impacting U.S. market with new models.
WHO essential medicines list now includes cancer and diabetes drugs, adding 20 new medicines for adults and 15 for children.
Gilead HIV drug prices increase significantly, while Novartis enters a $5.2 billion licensing deal with Argo Biopharmaceutical.
Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.
CVS Health will not add Gilead Sciences’ new HIV prevention drug to its commercial plans for now, despite the medicine’s proven effectiveness
Concerns are mounting in India over the UK-India Free Trade Agreement’s potential impact on access to affordable medicines. Experts fear the deal may weaken compulsory licensing norms, a crucial safeguard allowing generic drug production during public health emergencies
Mounjaro priced from Rs 14,000 for weekly administration. • Offers six dose strengths for personalized treatment. • Targets type 2 diabetes and obesity manageme